If you have type 2 diabetes, your doctor or health care provider has most likely prescribed you a long acting insulin like Lantus (insulin glargine), Toujeo (insulin glargine), or Basaglar (insulin glargine). These type of insulins work to control your blood sugar between meals and when you’re sleeping. They can be injected once or twice a day to give you around-the-clock blood sugar control.
Lusduna Nexvue (insulin glargine) is the newest brand of long-acting insulin to gain FDA approval.
What are insulin glargine products prescribed for?
Insulin glargine products are indicated to improve blood sugar control in adults and pediatric patients with type 1 diabetes, and adults with type 2 diabetes.
No. These insulin glargine products are considered new drugs and must be approved by the doctor as a new prescription. Although Basaglar, Lusduna, and Lantus share the same active ingredient, insulin glargine, they cannot be automatically substituted for one another unless you have approval from your doctor.
When will Lusduna be available?
Unsure. At this time Merck, the manufacturer of Lusduna, is involved in a patent infringement lawsuit with Sanofi, the manufacturer of both Lantus and Toujeo. Even though Lusduna has met all required standards for FDA approval, Lusduna has been tentatively approved and will be available in markets when the lawsuit is completed. Unfortunately, this could delay Lusduna’s release for even up to 30 months. Stay tuned, GoodRx will keep you updated!
For more information, read the press release from Merck here.